Author
Katalin Boér
Also Known As
K BOER, K Boer, K Boér, K. Boer, K. Boér, K. Böer, K. De Boer, K. de Boer, Kaissa de Boer, Katalin Boer
94
Publications
4.3K
Citations
21
H-Index
46
Concepts
All Affiliations
| # | Concept | H-Index | Publications | Citations |
|---|---|---|---|---|
1 | Medicine | 14 | 15 | 2.7K |
2 | Health Sciences | 3 | 3 | 81 |
3 | Engineering | 2 | 2 | 58 |
4 | Cell Biology | 2 | 2 | 183 |
5 | Public Health | 1 | 1 | 10 |
Katalin Boér
×
29
Publications
4K
Citations
20
H-Index
| Year | Citations | |
|---|---|---|
2014 | 1.9K | |
2021 | 364 | |
2011 | 269 | |
2016 | 180 | |
2020 | 164 | |
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens Jaafar Bennouna, István Láng, Manuel Valladares‐Ayerbes, Phase IiGastrointestinal OncologyMedicinePharmacologyPathology | 2010 | 139 |
2012 | 128 | |
2019 | 111 | |
2019 | 95 | |
2021 | 83 |
Page 1
Page 1